Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Deffered Revenue (2016 - 2023)

Plus Therapeutics has reported Non-Current Deffered Revenue over the past 12 years, most recently at $1.9 million for Q4 2023.

  • Quarterly Non-Current Deffered Revenue rose 17.1% to $1.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2023, up 17.1% year-over-year, with the annual reading at $1.9 million for FY2023, 17.1% up from the prior year.
  • Non-Current Deffered Revenue was $1.9 million for Q4 2023 at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $1.9 million in Q4 2023 and troughed at $142000.0 in Q1 2019.
  • The 3-year median for Non-Current Deffered Revenue is $1.6 million (2022), against an average of $1.2 million.
  • Year-over-year, Non-Current Deffered Revenue surged 35.24% in 2019 and then grew 17.1% in 2023.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $142000.0 in 2019, then soared by 1057.04% to $1.6 million in 2022, then grew by 17.1% to $1.9 million in 2023.
  • Per Business Quant, the three most recent readings for PSTV's Non-Current Deffered Revenue are $1.9 million (Q4 2023), $1.6 million (Q4 2022), and $142000.0 (Q1 2019).